Drug General Information
Drug ID	D05RGV
Former ID	DNCL002473
Drug Name	MK-1496
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 1	[522634]
Company	Merck
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Serine/threonine-protein kinase PLK1	Target Info	Inhibitor	[549710]
KEGG Pathway	FoxO signaling pathway
	Cell cycle
	Oocyte meiosis
	Progesterone-mediated oocyte maturation
Pathway Interaction Database	p73 transcription factor network
	ATR signaling pathway
	PLK1 signaling events
	FoxO family signaling
	FOXM1 transcription factor network
	Validated transcriptional targets of TAp63 isoforms
	Polo-like kinase signaling events in the cell cycle
Reactome	Polo-like kinase mediated events
	Golgi Cisternae Pericentriolar Stack Reorganization
	APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
	Phosphorylation of the APC/C
	Phosphorylation of Emi1
	Condensation of Prophase Chromosomes
	Separation of Sister Chromatids
	Resolution of Sister Chromatid Cohesion
	Regulation of PLK1 Activity at G2/M Transition
	Activation of NIMA Kinases NEK9, NEK6, NEK7
	Loss of Nlp from mitotic centrosomes
	Recruitment of mitotic centrosome proteins and complexes
	Loss of proteins required for interphase microtubule organization?from the centrosome
	Anchoring of the basal body to the plasma membrane
	RHO GTPases Activate Formins
	Mitotic Prometaphase
	Cyclin A/B1 associated events during G2/M transition
WikiPathways	Mitotic Telophase/Cytokinesis
	Mitotic Metaphase and Anaphase
	Mitotic Prophase
	Mitotic Prometaphase
	Integrated Pancreatic Cancer Pathway
	TNF alpha Signaling Pathway
	Prostate Cancer
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Mitotic G2-G2/M phases
	Cell Cycle
	APC/C-mediated degradation of cell cycle proteins
	Regulation of toll-like receptor signaling pathway
References
Ref 522634	ClinicalTrials.gov (NCT00880568) Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED). U.S. National Institutes of Health.
Ref 549710	J Clin Oncol 29: 2011 (suppl; abstr 3012).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.